Compare AEG & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AEG | CRL |
|---|---|---|
| Founded | 1983 | 1947 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 13.1B |
| IPO Year | 1997 | 1999 |
| Metric | AEG | CRL |
|---|---|---|
| Price | $8.30 | $339.31 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 17 |
| Target Price | $9.88 | ★ $318.87 |
| AVG Volume (30 Days) | ★ 6.4M | 1.2M |
| Earning Date | 02-09-2023 | 11-04-2026 |
| Dividend Yield | ★ 4.88% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 6.48 |
| Revenue | N/A | ★ $1,857,601,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.99 | $2.53 |
| P/E Ratio | ★ $7.91 | $50.35 |
| Revenue Growth | N/A | ★ 10.48 |
| 52 Week Low | $6.75 | $146.20 |
| 52 Week High | $9.64 | $379.63 |
| Indicator | AEG | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 46.84 | 53.12 |
| Support Level | $8.17 | $151.03 |
| Resistance Level | $8.43 | $379.63 |
| Average True Range (ATR) | 0.10 | 19.27 |
| MACD | 0.05 | -3.83 |
| Stochastic Oscillator | 47.93 | 41.54 |
Aegon is a life insurance and long-term savings business listed in the Netherlands. It was listed on the Amsterdam Stock Exchange in the 1980s and now has mature operations in the United States, the United Kingdom, and four growth markets of Brazil, China, Portugal, and Spain. In recent years, Aegon has been moving through an extensive transformation program during which management has sought to divest noncore operations and improve the risk profile of the business. Financial assets are the parts of the company that are now being run off. Aegon is looking to cycle out of capital-consumptive and volatile earnings products and recycle capital into capital-light and more predictable strategic businesses.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.